Federated Hermes
VERV

Federated Hermes’s Verve Therapeutics VERV Stock Holding History

Federated Hermes’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,645
Closed -$29.7K – 2240
2025
Q2 		$29.7K Buy
2,645
+2,344
+779% +$13.4K ﹤0.01% 1680
2025
Q1 		$1.38K Sell
301
-6,659
-96% -$44.6K ﹤0.01% 1982
2024
Q4 		$39.3K Sell
6,960
-899
-11% -$5.07K ﹤0.01% 1717
2024
Q3 		$38K Sell
7,859
-1,143,691
-99% -$6.64M ﹤0.01% 1695
2024
Q2 		$5.62M Sell
1,151,550
-2,405,027
-68% -$15.1M 0.01% 687
2024
Q1 		$47.2M Sell
3,556,577
-423,795
-11% -$5.62M 0.11% 234
2023
Q4 		$55.5M Buy
3,980,372
+1,448,003
+57% +$17.9M 0.14% 194
2023
Q3 		$33.6M Buy
2,532,369
+129,729
+5% +$2.09M 0.09% 262
2023
Q2 		$45M Hold
2,402,640
– – 0.11% 224
2023
Q1 		$34.6M Buy
2,402,640
+324,351
+16% +$6.35M 0.09% 266
2022
Q4 		$40.2M Buy
2,078,289
+328,552
+19% +$8.71M 0.11% 233
2022
Q3 		$60.1M Buy
1,749,737
+651,900
+59% +$20.8M 0.18% 145
2022
Q2 		$16.8M Buy
1,097,837
+387,600
+55% +$6M 0.05% 435
2022
Q1 		$16.2M Buy
710,237
+340,237
+92% +$9.72M 0.04% 492
2021
Q4 		$13.6M Hold
370,000
– – 0.03% 576
2021
Q3 		$17.4M Hold
370,000
– – 0.03% 509
2021
Q2 		$22.3M Buy
+370,000
New +$15.4M 0.04% 452

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Federated Hermes's VERV Position: Q3 2025 in Review

Federated Hermes sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,645 shares — an estimated $29.7K sold.

Federated Hermes first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $60.1M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Federated Hermes reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 2,645 Verve Therapeutics shares in Q3 2025, an estimated $29.7K.
  • Federated Hermes first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Federated Hermes's Verve Therapeutics position peaked at $60.1M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.